The Rohatyn Group Completes Investment in European Contract Research Organization, Optimapharm

The Rohatyn Group (“TRG”), an emerging markets focused asset management firm, announced Tuesday that it has completed an investment in Optimapharm d.d. (“Optimapharm” or the “Company”), to establish a partnership with the company’s founders Gordana Gregurić Čičak and Igor Čičak. Optimapharm is a contract research organization (“CRO”) managing clinical trials on behalf of leading biotech, pharma and medical devices companies in 22 countries throughout Europe. Founded in 2006 in Croatia, Optimapharm is a full service mid-sized CRO with expertise in managing trials across Europe, providing tailored solutions and offering differentiated access to patients. With premium professional services and competitive costs at high industry standards, the Company has had a repeat business rate of over 95%. With TRG’s investment, Optimapharm will seek to continue to grow both organically and through strategic acquisitions.

Read the full article: The Rohatyn Group Completes Investment in European Contract Research Organization, Optimapharm //

Source: https://www.businesswire.com/news/home/20200512005718/en/Rohatyn-Group-Completes-Investment-European-Contract-Research

Scroll to Top